Tzortzatou-Stathopoulou F, Xaidara A, Mikraki V, Moschovi M, Arvanitis D, Ageloyianni P, Prodromou P
First Department of Pediatrics, University of Athens, Agia Sophia Children's Hospital, Greece.
Med Pediatr Oncol. 1995 Aug;25(2):74-8. doi: 10.1002/mpo.2950250205.
Twenty-three children with Langerhans' cell histiocytosis (LCH) have been treated with trimethoprim-sulphamethoxazole (T-S) in a 4-year period. The children are classified in two main groups according to the extent of their disease. Group A includes 16 children with single system disease and group B, seven children with multisystem disease. All patients were treated for 4 weeks to 3 months. The results of treatment are evaluated in terms of response in individual organs involved. All children with single system disease had a good response to the drug. Children with multisystem disease had a good response to some organs but a poorer outcome for the lungs and for the blood. These patients did not respond even to conventional chemotherapy.
在4年时间里，23名朗格汉斯细胞组织细胞增多症（LCH）患儿接受了甲氧苄啶 - 磺胺甲恶唑（T - S）治疗。根据疾病程度，这些患儿被分为两个主要组。A组包括16名单系统疾病患儿，B组包括7名多系统疾病患儿。所有患者接受了4周 至3个月的治疗。根据受累各个器官的反应来评估治疗结果。所有单系统疾病患儿对该药物反应良好。多系统疾病患儿对某些器官反应良好，但肺部和血液方面的预后较差。这些患者甚至对传统化疗也没有反应。
